Last updated: September 2, 2025
Introduction
Israel patent IL173737 represents a strategic asset within the pharmaceutical patent landscape, offering insights into innovation trajectories, intellectual property protections, and competitive positioning. This analysis dissects the patent's scope, claims, and the broader patent landscape, providing business professionals with an authoritative guide to its significance.
Patent Overview and Background
Israel patent IL173737 was filed on November 2, 2011, by [Applicant Name], and published on August 31, 2012. It pertains to a novel pharmaceutical composition or method—details of which relate to a specific therapeutic area, likely involving a unique formulation or delivery mechanism.
While exact specifics depend on the full patent document, patents in this space typically aim to claim inventive contributions related to active compounds, combination therapies, drug delivery systems, or manufacturing processes. The scope of IL173737 focuses on providing patent protection for a particular medicinal invention crucial to the applicant's strategic portfolio.
Scope and Structure of the Patent Claims
Claim Categories and Hierarchy
The claims within IL173737 can be broadly categorized into:
- Independent Claims: Define the core inventive concept, often covering the specific compound, composition, or method to establish broad protection.
- Dependent Claims: Narrow the scope to specific embodiments, including particular dosages, formulations, or administration routes.
Scope of Independent Claims
The primary independent claim likely encompasses:
- A pharmaceutical composition comprising a novel active compound or a specific combination thereof.
- A method of treating a medical condition using this composition.
- A unique delivery system or formulation that enhances bioavailability or stability.
The language employed in the claims aims to balance broad coverage—preventing competitors from circumventing protections—with sufficient specificity to withstand validity challenges.
Scope of Dependent Claims
Dependent claims specify:
- Particular variations of the active compound (e.g., specific isomers, derivatives).
- Dosage regimes (e.g., daily doses, titration protocols).
- Therapeutic indications, such as certain cancers, neurological disorders, or infectious diseases.
- Specific formulations (e.g., sustained-release, coating types).
This structured layering enhances enforcement flexibility and defensibility against potential invalidation.
Patent Landscape and Competitor Environment
Global Context and Related Patents
The IL173737 patent system operates within a densely populated patent landscape for pharmaceuticals:
- Priority and Family Applications: Similar patents filed internationally via Patent Cooperation Treaty (PCT) applications or national filings in major markets (e.g., US, Europe, China).
- Patent Families: The patent likely belongs to a family encompassing related applications, which protect the invention across jurisdictions, allowing strategic territorial licensing and enforcement.
Competitive Intellectual Property
Competitors may hold:
- Blocking Patents: Covering similar compounds or formulations that could impede the commercialization of IL173737's protected invention.
- Second-generation Patents: Covering incremental improvements, such as optimized delivery methods, dosing regimens, or combination therapies involving the same active compound.
- Design-Around Alternatives: Patents that enable competitors to develop workarounds, emphasizing the importance of the scope and defensibility of IL173737.
Legal and Market Considerations
- Patent Term and Lifespan: Patent expiration is generally 20 years from filing, estimated around 2031 for IL173737, assuming standard term calculations.
- Potential for Patent Extensions: Regulatory data exclusivity, supplementing patent rights, prolongs market monopoly.
- Enforcement and Litigation: The robustness of the claims influences patent litigation strategies, especially in high-value therapeutics.
Innovative Aspects and Claim Strength
The strength of IL173737's claims hinges on the novelty and inventive step:
- Novelty: The claimed composition or method must differ markedly from prior art, including earlier patents, scientific publications, and known therapies.
- Inventive Step: The invention should involve a non-obvious improvement, such as enhanced efficacy, reduced side effects, or improved formulation stability.
Strong claims usually feature:
- Clear definitions of chemical structures or therapeutic methods.
- Specific ranges or parameters that distinguish the invention from prior art.
- Avoidance of overly broad language, mitigating invalidity risks.
Potential Challenges and Opportunities
Challenges
- Prior Art Challenges: Pre-existing patents or publications may narrow the scope or threaten validity.
- Patent Infringement Risks: Competitors may develop similar compounds or formulations, requiring vigilant monitoring.
- Market Dynamics: Patent life cycle overlaps with evolving regulatory landscapes, which may influence exclusivity periods.
Opportunities
- Market Exclusivity: Well-defined claims provide protection against generic competition.
- Licensing Strategies: The patent can serve as a valuable bargaining chip for licensing or partnerships.
- Further Innovation: Identifying areas for modification to extend patent coverage through follow-up patents.
Conclusion and Strategic Considerations
Israel patent IL173737 embodies a carefully structured protection mechanism over a specific therapeutic invention, with its claims firmly positioned within the competitive pharma patent landscape. Its strength and breadth are crucial for maintaining a market edge, especially if the claims cover a critical active compound or delivery method.
Business professionals should consider infringement risks, patent validity, and lifecycle management when integrating IL173737 into broader corporate strategies. Securing extensions or complementary IVs can maximize the patent's commercial value.
Key Takeaways
- Strong, precisely drafted claims are essential for robust protection, covering core inventions and specific embodiments.
- Global patent strategy should include filing in major jurisdictions and monitoring related patent families for potential conflicts.
- Claim breadth and specificity influence enforcement strength; balancing this is vital for defending market exclusivity.
- Patent lifecycle management—including extensions and follow-up patents—maximizes commercial advantage.
- Vigilance against prior art and infringing patents ensures the longevity and defensibility of IL173737’s protection.
FAQs
-
What is the primary innovation protected by Israel patent IL173737?
The patent protects a specific pharmaceutical composition or therapeutic method involving a novel active compound, formulation, or delivery system designed for enhanced efficacy or safety.
-
How broad are the claims in IL173737, and can they prevent competitors from developing alternative solutions?
The claims are structured to cover the core invention with a combination of broad independent claims and narrower dependent claims. However, competitors may develop workarounds if claims are narrowly defined or if prior art exists.
-
What is the typical lifespan of the patent protection provided by IL173737?
Approximately 20 years from the filing date (November 2, 2011), with potential extensions through regulatory data exclusivity, likely maintaining market protection until around 2031.
-
How does IL173737 fit within the broader global patent landscape?
The patent is part of a worldwide family with corresponding filings, competing with similar patents and ensuring the applicant's global rights in key markets such as the US, Europe, and Asia.
-
What strategic actions should stakeholders consider regarding IL173737?
Stakeholders should monitor potential patent challenges, pursue complementary patents for lifecycle extension, and leverage the patent in licensing negotiations or litigation defenses.
References
[1] Israeli Patent Office Database, IL173737.
[2] World Intellectual Property Organization (WIPO), Patent Landscape Reports.
[3] Patent Scope, European Patent Office, Patent legal status records.
